» Authors » J Grooten

J Grooten

Explore the profile of J Grooten including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 55
Citations 1284
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
De Koker S, Van Hoecke L, De Beuckelaer A, Roose K, Deswarte K, Willart M, et al.
Sci Rep . 2017 Jul; 7(1):5986. PMID: 28729715
Due to their capacity to skew T cell responses towards Th1 oriented immunity, oligonucleotides containing unmethylated CpG motifs (CpG) have emerged as interesting adjuvants for vaccination. Whereas the signalling pathways...
2.
Dejager L, Dendoncker K, Eggermont M, Souffriau J, Van Hauwermeiren F, Willart M, et al.
Mucosal Immunol . 2015 Mar; 8(6):1212-25. PMID: 25760421
Asthma is a heterogeneous disorder, evidenced by distinct types of inflammation resulting in different responsiveness to therapy with glucocorticoids (GCs). Tumor necrosis factor α (TNFα) is involved in asthma pathogenesis,...
3.
Tournoy K, Hove C, Grooten J, Moerloose K, Brusselle G, Joos G
Clin Exp Allergy . 2006 Jan; 36(1):8-20. PMID: 16393260
Non-specific anti-inflammatory medication is actually the treatment of choice for controlling the T-helper type 2 (Th-2) cell-driven airway inflammation in asthma. The induction of counterbalancing Th-1 cell clones, long considered...
4.
Fordel E, Geuens E, Dewilde S, Rottiers P, Carmeliet P, Grooten J, et al.
Biochem Biophys Res Commun . 2004 Jun; 319(2):342-8. PMID: 15178412
The vertebrate globin family has been extended with two members: neuroglobin and cytoglobin. We here investigate the changes of expression levels upon hypoxia of cytoglobin in parallel with neuroglobin, in...
5.
Matthys P, Dooms H, Rottiers P, Mitera T, Overgergh L, Leclercq G, et al.
Clin Exp Immunol . 2002 Nov; 130(3):379-85. PMID: 12452826
TCR/CD3 aggregation by injection of anti-CD3 Ab produces T cell activation, release of cytokines such as IFN-gamma, and apoptosis in the cortical region of the thymus. We show that anti-CD3...
6.
Denecker G, Vercammen D, Steemans M, Vanden Berghe T, Brouckaert G, van Loo G, et al.
Cell Death Differ . 2001 Aug; 8(8):829-40. PMID: 11526436
In L929sAhFas cells, tumor necrosis factor (TNF) leads to necrotic cell death, whereas agonistic anti-Fas antibodies elicit apoptotic cell death. Apoptosis, but not necrosis, is correlated with a rapid externalization...
7.
Schoonjans R, Willems A, Schoonooghe S, Leoen J, Grooten J, Mertens N
Biomol Eng . 2001 May; 17(6):193-202. PMID: 11337278
Due to their specificity and versatility in use, bispecific antibodies (BsAbs) are promising therapeutic tools in tomorrow's medicine, provided sufficient BsAb can be produced. Expression systems favoring efficient heterodimerization of...
8.
Goossens V, Stange G, Moens K, Pipeleers D, Grooten J
Antioxid Redox Signal . 2001 Mar; 1(3):285-95. PMID: 11229440
Tumor necrosis factor (TNF) induces a caspase-independent but mitochondria-dependent cell death process in the mouse fibrosarcoma cell line L929. Mitochondria actively participate in this TNF-induced necrotic cell death by the...
9.
Schoonjans R, Willems A, Schoonooghe S, Fiers W, Grooten J, Mertens N
J Immunol . 2000 Dec; 165(12):7050-7. PMID: 11120833
Due to their multispecificity and versatility, bispecific Abs (BsAbs) are promising therapeutic tools in tomorrow's medicine. Especially intermediate-sized BsAbs that combine body retention with tissue penetration are valuable for therapy...
10.
Schoonjans R, Willems A, Grooten J, Mertens N
Bioseparation . 2000 Dec; 9(3):179-83. PMID: 11105248
Bispecific antibodies (BsAb) are promising therapeutic tools in tomorrow's medicine. Expression systems favoring efficient heterodimerization of intermediate-sized bispecific antibodies will significantly improve existing production methods. By C-terminal fusion of scFv...